FDA Approves Pembrolizumab Plus Chemo for TNBC
November 14th 2020The FDA granted an accelerated approval to pembrolizumab (Keytruda) plus chemotherapy for the treatment of patients with locally recurrent, unresectable or metastatic triple-negative breast cancer (TNBC) with PD-L1 expression is CPS ≥10, according to the agency.
FDA Approves Venetoclax Combinations for Certain AML Indications
October 16th 2020The FDA approved venetoclax (Venclexa) plus azacitadine, decitabine, or low-dose cytarabine (LDAC) for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) who are 75 years or older or have comorbidities that make them ineligible for intensive induction chemotherapy.